Semler Scientific, Inc. (SMLR) Q2 2025 Earnings Call Transcript

Semler Scientific (SMLR) reported Q2 2025 GAAP net income of $66.9 million, or $5.04 per diluted share, primarily attributed to an $83.8 million unrealized gain from its Bitcoin holdings, despite a decline in its healthcare revenue to $8.2 million. The company aggressively expanded its Bitcoin treasury to 5,021 BTC, valued at $586.2 million as of July 31, funded through healthcare cash flow, convertible debt, and ATM equity issuances, with ambitious targets to reach 105,000 BTC by year-end 2027. Management emphasized its 'dual-engine' strategy and belief that the stock is 'absurdly undervalued,' seeking to amplify shareholder exposure to Bitcoin through intelligent leverage and capital market flexibility, while also spinning out a new healthcare subsidiary, CardioVanta, for future growth.

Analysis

Semler Scientific's Q2 2025 results illustrate its strategic pivot into a leveraged Bitcoin treasury vehicle, with financial performance now dominated by its crypto-asset holdings. The company reported a GAAP net income of $66.9 million, or $5.04 per diluted share, a figure almost entirely attributable to an $83.8 million unrealized gain on its Bitcoin portfolio. This masks a decline in the core healthcare business, which saw revenues fall to $8.2 million and posted a $1.2 million loss from operations, attributed to CMS reimbursement headwinds. Management is aggressively pursuing a 'dual-engine' strategy, using capital from its at-the-market (ATM) equity offerings, which raised $156.6 million in Q2, to rapidly expand its crypto holdings to 5,021 BTC (valued at $586 million as of July 31). The executive team has articulated extremely ambitious targets, aiming to hold 105,000 BTC by year-end 2027, and explicitly stated its intent to use additional leverage to amplify shareholder returns. Management believes the stock is 'absurdly undervalued,' a claim supported by a stated 1.7x annualized P/E ratio that is distorted by non-cash crypto gains, and is positioning the company as an essential equity proxy for institutions seeking Bitcoin exposure, a strategy they believe justifies a premium to its Bitcoin net asset value (mNAV).

Key Decisions for Investors

• Investors should primarily evaluate Semler Scientific as a leveraged Bitcoin proxy, as its valuation and performance are now inextricably linked to Bitcoin's price volatility and the company's ability to execute its capital markets strategy, rather than the fundamentals of its legacy healthcare operations.
• Consider the significant execution risk associated with the company's ambitious Bitcoin accumulation targets, which depend heavily on continued access to capital markets through share dilution via its ATM offering and the potential issuance of new debt.
• Monitor the performance of the core healthcare business and the new CardioVanta subsidiary, as its ability to generate positive free cash flow is a key component of management's narrative for funding non-dilutive Bitcoin purchases.
• Be cautious of management's valuation claims, such as the 1.7x P/E ratio, as it is based on non-cash, mark-to-market accounting for crypto assets and does not reflect the underlying operational profitability of the enterprise.